rbd317
9 years ago
Critical Outcome Technologies Inc. (COT) to Present at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on June 10
NEW YORK, June 4, 2015 (GLOBE NEWSWIRE) -- Critical Outcome Technologies Inc. (TSXV:COT), a bioinformatics company, will be presenting the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on Wednesday, June 10. The event is a gathering of the brightest emerging growth small-cap and pre-IPO companies to present and network with an exclusive group of top-level institutional investors.
Critical Outcome Technologies Inc.: Wayne Danter, Co-Founder and CEO
Time: 1:10 – 1:30 pm (ET)
Equities.com designed this full-day event dedicated to creating unparalleled discovery and exclusive networking sessions. For more details on the conference, please visit http://www.equitiesevents.com.
Registration for the conference is still available but space is limited. We encourage you to register by clicking this link (http://bit.ly/1Q7aMRx) as soon as possible to ensure your participation. Presenters and attendees can schedule private one-on-one meetings to maximize their networking opportunities.
Participation in this exclusive conference is for institutional investors interested in small-cap and pre-IPO opportunities. In attendance will be: Hedge Funds, Family Offices, Portfolio Managers, Investment Banks and Venture Capitalists.
To learn more about how you can participate and to stay up-to-date on all conference-related news, please visit www.equitiesevents.com.
To register for the conference, please visit: http://bit.ly/1Q7aMRx
- See more at: http://globenewswire.com/news-release/2015/06/04/742144/10137285/en/Critical-Outcome-Technologies-Inc-COT-to-Present-at-the-Small-Cap-Stars-Spring-Conference-2015-at-Convene-in-Times-Square-New-York-on-June-10.html#sthash.wYQKk0du.dpuf
$COT.V $COTQF
ddninja
9 years ago
Critical Outcome Gets Boost from FDA for New Cancer Treatment, COTI-2
http://www.biopharmadive.com/press-release/20150527-critical-outcome-gets-boost-from-fda-for-new-cancer-treatment-coti-2/
London, Ontario (May 27, 2015): Critical Outcome Technologies Inc. (“COTI” or the “Company”) (TSX Venture: COT; OTCQB: COTQF), announced today that the U.S. Food and Drug Administration (“FDA”) granted investigational new drug status (“IND”) for COTI-2, the Company’s small molecule activator of misfolded mutant p53 protein, in gynecological cancers.
“The grant of this IND marks the achievement of the second important milestone for COTI-2 in 2015 and builds on the Orphan Drug designation received for ovarian cancer from the FDA in June 2014,” said Dr. Wayne Danter, President and CEO. “During preclinical studies, COTI-2 with its novel mechanism of action demonstrated selective and potent anti-cancer p53-dependent activity in many cancers. We look forward to reproducing these encouraging results in a clinical setting and confirming that COTI-2 is a highly promising novel treatment option for women with gynecological cancers having p53 mutations.”
The Company plans to commence a Phase 1 clinical trial in the second half of calendar 2015 in partnership with the University of Texas, MD Anderson Cancer Center in Houston. The grant of this IND triggers the issuance of 715,720 common shares of the Company as final payment of contingent share consideration that arose on the acquisition of DDP Therapeutics in November 2007.
$COTQF ~ $COT.V
rbd317
9 years ago
FDA Grants IND to Critical Outcome Technologies for COTI-2, the Company's Activator of Mutant p53 Protein
Company Finalizing Plans to Commence Clinical Trial for COTI-2 in the Second Half of 2015
http://www.marketwired.com/press-release/-2023097.htm
LONDON, ON--(Marketwired - May 26, 2015) - Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE: COT) (OTCQB: COTQF), announced today that the U.S. Food and Drug Administration ("FDA") granted investigational new drug status ("IND") for COTI-2, the Company's small molecule activator of misfolded mutant p53 protein, in gynecological cancers.
"The grant of this IND marks the achievement of the second important milestone for COTI-2 in 2015 and builds on the Orphan Drug designation received for ovarian cancer from the FDA in June 2014," said Dr. Wayne Danter, President and CEO. "During preclinical studies, COTI-2 with its novel mechanism of action demonstrated selective and potent anti-cancer p53-dependent activity in many cancers. We look forward to reproducing these encouraging results in a clinical setting and confirming that COTI-2 is a highly promising novel treatment option for women with gynecological cancers having p53 mutations."
The Company plans to commence a Phase 1 clinical trial in the second half of calendar 2015 in partnership with the University of Texas, MD Anderson Cancer Center in Houston.
The grant of this IND triggers the issuance of 715,720 common shares of the Company as final payment of contingent share consideration that arose on the acquisition of DDP Therapeutics in November 2007.
About COTI-2
COTI-2 is a small molecule activator of misfolded mutant p53 protein approved for clinical development. Extensive studies have demonstrated COTI-2's ability to restore mutant p53 function and thus induce cancer cell death in many common p53 mutations. Mutations of the p53 gene are the most common genetic alterations in human cancers, occurring in a wide range of cancers, including ovarian, lung, colorectal, breast, liver, bladder and other cancers. COTI-2's specific protein target, low toxicity, combination effectiveness with standard agents, and potential for longer term outpatient therapy as an oral agent, supports a dramatic change in the treatment of susceptible cancers.
$COTQF $COT.V
ddninja
10 years ago
Critical Outcome Technologies Adds First European Patent to Growing Intellectual Property Protection for COTI-2
http://www.marketwired.com/press-release/-2018405.htm
LONDON, ON--(Marketwired - May 11, 2015) - Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE: COT)(OTCQB: COTQF) announced today that the European Patent Office has granted the Company European Patent No. 2121681 for its lead cancer drug candidate, COTI-2. This patent covers the composition of matter of COTI-2, the Company's small molecule activator of misfolded mutant p53 protein. Issuance of this European patent provides the Company with additional protection and licensing opportunities for the COTI-2 franchise in European markets.
"COTI-2's overall patent protection continues to strengthen as we prepare for our upcoming Phase 1 clinical trial in gynecologic cancers," said Dr. Wayne Danter, President and CEO of COTI. "With nine patents now issued for COTI-2 and several more pending worldwide, we have a growing intellectual property position protecting COTI-2 that supports our efforts to maximize future commercial licensing opportunities."
European Patent No. 2121681 covers a number of chemical structures in the COTI-2 family of compounds, pharmaceutical preparations containing COTI-2, methods of manufacturing the compounds and use of the compounds in the treatment of cancer in the European market until January 2028. This subject matter has previously been protected with patents in the U.S., Japan and Canada.
$COT.V ~ $COTQF
rbd317
10 years ago
Critical Outcome Technologies Files Investigational New Drug Application With the FDA for COTI-2
#COTQF / #COT.V
Novel p53-Dependent Cancer Therapy One Step Closer to the Clinic
http://www.marketwired.com/press-release/-2013503.htm
LONDON, ON--(Marketwired - April 27, 2015) - Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE: COT) (OTCQB: COTQF), announced today the filing of an Investigational New Drug ("IND") application with the U.S. Food and Drug Administration's Center for Drug Evaluation and Research ("FDA") for COTI-2, a potential breakthrough therapy intended for the treatment of women with gynecological cancers with p53 mutations. Advanced gynecological cancers have a particularly high prevalence rate (as high as 95%) of p53 mutations. The IND application is a complete description of the chemistry, non-clinical pharmacodynamics and pharmacokinetics, safety toxicology, manufacturing and other relevant information related to COTI-2 as a potential treatment for patients with p53 mutations.
Subject to the FDA granting the IND application, the Company intends to initiate a Phase 1 clinical trial of an oral formulation of COTI-2 in patients with gynecological cancers (cervical, endometrial and ovarian) at the University of Texas MD Anderson Cancer Center in Houston. Extensive preclinical studies have demonstrated COTI-2's ability to restore mutant p53 function and thus induce cancer cell death in cancers with many common p53 mutations. In the upcoming clinical trial, the Company intends to determine primarily the safety of COTI-2, as well as obtain some indications of efficacy, the maximum tolerated-dose and pharmacokinetics in treating gynecological cancers containing p53 mutations in patients who have failed the current first line therapies used in these types of cancers.
"The filing of this IND application is a critical step forward in moving our lead oncology asset into the clinic," said Dr. Wayne Danter, President and CEO. "With a novel mechanism of action, orphan drug status for ovarian cancer, and a strong clinical development partner in MD Anderson, we believe that COTI-2 is well positioned for a Phase 1 clinical trial in gynecological cancers. Most ovarian cancers have at least one p53 mutation and COTI-2 may represent a potential breakthrough therapy for patients with these mutations. We look forward to working with the FDA in anticipation of their granting the IND application in the near future and commencing our COTI-2 trial for the benefit of women with gynecological cancers who have failed standard therapies."
For additional information pertaining to gynecological cancers, please visit our blog at www.criticaloutcomeblog.com/blog-posts.
Circuit_Racer
10 years ago
April 15, 2015 08:30 ET
Critical Outcome Technologies Receives First U.S. Patent for Next Generation HIV Treatment
Second Generation HIV Integrase Inhibitor Compounds Discovered Using Proprietary Drug Discovery Platform Technology, CHEMSAS®
LONDON, ON--(Marketwired - April 15, 2015) - Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE: COT) (OTCQB: COTQF) announced today that it has been granted a U.S. patent for the Company's novel HIV integrase inhibitor compounds.
"This important patent is our first for the treatment of HIV and validates our research as we look to identify the lead compound to advance through preclinical development," said Dr. Wayne Danter, President and CEO of COTI. "The highly novel compounds covered by this patent were discovered using our proprietary drug discovery platform technology, CHEMSAS®. Once selected, the final lead compound will be developed as a second generation HIV integrase inhibitor with a unique mode of action that differentiates it from current integrase inhibitor programs in the market or in development."
United States Patent No. 8987272 covers novel compounds useful in the treatment of HIV and methods of treating HIV using the compounds. The patent provides coverage for these compounds and methods until the year 2031. Equivalent patents are pending in Canada and Europe.
The Company is currently looking for a licensing or co-development partner for this preclinical program.
For additional information pertaining to this announcement, please visit our blog at www.criticaloutcomeblog.com/blog-posts.
About Critical Outcome Technologies Inc.
COTI is a biopharmaceutical company using machine learning to rapidly develop targeted therapies. COTI's proprietary artificial intelligence platform, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.
Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome
Notice to Readers
Information contained in this press release may contain certain statements, which constitute "forward- looking statements" within the meaning of the Securities Act (Ontario) and applicable securities laws. For example, the statements "…as we look to identify the lead compound to advance through preclinical development" and "once selected, the final lead compound will be developed as a second generation HIV integrase inhibitor with a unique mode of action that differentiates it from current integrase inhibitor programs in the market or in development" and "equivalent patents are pending in Canada and Europe" and "currently looking for a licensing or co-development partner for this preclinical program," are forward-looking statements. Forward-looking statements, by their nature, are not guarantees of future performance and are based upon management's current expectations, estimates, projections and assumptions. COTI operates in a highly competitive environment that involves significant risks and uncertainties, which could cause actual results to differ materially from those anticipated in these forward-looking statements. Management of COTI considers the assumptions on which these forward-looking statements are based to be reasonable, but as a result of the many risk factors, cautions the reader that actual results could differ materially from those expressed or implied in these forward-looking statements. Information in this press release should be considered accurate only as of the date of the release and may be superseded by more recent information disclosed in later press releases, filings with the securities regulatory authorities or otherwise.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information, visit www.criticaloutcome.com or:
Contact Information
Contact:
Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO
Tel: 519-858-5157
Email: wdanter@criticaloutcome.com
Heisler Communications
Trevor Heisler
Investor Relations - Canada
Tel: 416-500-8061
Email: trevor@heislercommunications.com
Stonegate Capital Partners
Casey Stegman
Investor Relations - United States
Tel: 972-850-2001
Email: Casey@stonegateinc.com
ddninja
10 years ago
Wed, Apr 15, 2015: Critical Outcome Technologies Receives First U.S. Patent for Next Generation HIV Treatment
http://finance.yahoo.com/news/critical-outcome-technologies-receives-first-123000747.html
Second Generation HIV Integrase Inhibitor Compounds Discovered Using Proprietary Drug Discovery Platform Technology, CHEMSAS(R)
LONDON, ON--(Marketwired - April 15, 2015) - Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE: COT) (COTQF) announced today that it has been granted a U.S. patent for the Company's novel HIV integrase inhibitor compounds.
"This important patent is our first for the treatment of HIV and validates our research as we look to identify the lead compound to advance through preclinical development," said Dr. Wayne Danter, President and CEO of COTI. "The highly novel compounds covered by this patent were discovered using our proprietary drug discovery platform technology, CHEMSAS®. Once selected, the final lead compound will be developed as a second generation HIV integrase inhibitor with a unique mode of action that differentiates it from current integrase inhibitor programs in the market or in development."
United States Patent No. 8987272 covers novel compounds useful in the treatment of HIV and methods of treating HIV using the compounds. The patent provides coverage for these compounds and methods until the year 2031. Equivalent patents are pending in Canada and Europe.
The Company is currently looking for a licensing or co-development partner for this preclinical program.
For additional information pertaining to this announcement, please visit our blog at www.criticaloutcomeblog.com/blog-posts.
About Critical Outcome Technologies Inc.
COTI is a biopharmaceutical company using machine learning to rapidly develop targeted therapies. COTI's proprietary artificial intelligence platform, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.
Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Renee
7 years ago
Hot Features
Premium
